Cyclooxygenase Allosterism, Fatty Acid-mediated Cross-talk between Monomers of Cyclooxygenase Homodimers. - Wikidata - awgldk - TriplyDB

Cyclooxygenase Allosterism, Fatty Acid-mediated Cross-talk between Monomers of Cyclooxygenase Homodimers.

Cyclooxygenase Allosterism, Fatty Acid-mediated Cross-talk between Monomers of Cyclooxygenase Homodimers.

http://www.wikidata.org/entity/Q37149507

about

Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: relevance and clinical implications Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1 Structural Basis for L-Lysine Feedback Inhibition of Homocitrate Synthase Structural Basis of Fatty Acid Substrate Binding to Cyclooxygenase-2 Comparison of Cyclooxygenase-1 Crystal Structures: Cross-Talk between Monomers Comprising Cyclooxygenase-1 Homodimers,The Structural Basis of Endocannabinoid Oxygenation by Cyclooxygenase-2 Investigating Substrate Promiscuity in Cyclooxygenase-2: THE ROLE OF ARG-120 AND RESIDUES LINING THE HYDROPHOBIC GROOVE Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward Therapies targeting lipid peroxidation in traumatic brain injury Conservative Secondary Shell Substitution In Cyclooxygenase-2 Reduces Inhibition by Indomethacin Amides and Esters via Altered Enzyme Dynamics.Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation Asymmetric acetylation of the cyclooxygenase-2 homodimer by aspirin and its effects on the oxygenation of arachidonic, eicosapentaenoic, and docosahexaenoic acids.Dimerization of human 5-lipoxygenase.Prostaglandins and inflammation.GPIHBP1, an endothelial cell transporter for lipoprotein lipase.Biomarkers for personalizing omega-3 fatty acid dosing.Activation of the protein deacetylase SIRT6 by long-chain fatty acids and widespread deacylation by mammalian sirtuins.Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism.The structure of ibuprofen bound to cyclooxygenase-2.A cyclooxygenase-2-dependent prostaglandin E2 biosynthetic system in the Golgi apparatus 13-Methylarachidonic acid is a positive allosteric modulator of endocannabinoid oxygenation by cyclooxygenase.Action at a distance: mutations of peripheral residues transform rapid reversible inhibitors to slow, tight binders of cyclooxygenase-2.Human cyclooxygenase-1 activity and its responses to COX inhibitors are allosterically regulated by nonsubstrate fatty acids.Phosphatidylinositol-4-phosphate 5-kinase isoforms exhibit acyl chain selectivity for both substrate and lipid activator Intestinal smooth muscle dysfunction develops postnatally in cystic fibrosis mice Different Fatty Acids Compete with Arachidonic Acid for Binding to the Allosteric or Catalytic Subunits of Cyclooxygenases to Regulate Prostanoid Synthesis.Crystal Structure of Aspirin-Acetylated Human Cyclooxygenase-2: Insight into the Formation of Products with Reversed Stereochemistry.Biochemistry and pathophysiology of intravascular and intracellular lipolysis.Eicosanoids in metabolic syndrome.Major urinary metabolites of 6-keto-prostaglandin F2α in mice.Interactions of 2-O-arachidonylglycerol ether and ibuprofen with the allosteric and catalytic subunits of human COX-2.Increased saturated fatty acids in obesity alter resolution of inflammation in part by stimulating prostaglandin production Substrate-selective Inhibition of Cyclooxygeanse-2 by Fenamic Acid Derivatives Is Dependent on Peroxide Tone Pre-existent asymmetry in the human cyclooxygenase-2 sequence homodimer.Mechanistic and pharmacological issues of aspirin as an anticancer agent.Prostaglandin H synthase: resolved and unresolved mechanistic issues.

P2860

Q24630614-AFE42F5E-002C-4B57-BE15-B225BA1ED8C2 Q24632466-BA43D4FA-7B01-4A8A-BE10-BAB8B1E4ACDD Q24657423-4730ED22-A5BE-4D9F-A563-ABBF1FB03EE9 Q26823256-1003B553-3CD1-4608-817E-5D46F4849CE4 Q26852195-04F74B6C-2130-40BF-9D3E-8739980F6861 Q27658412-5352F6C1-6BB6-42B0-96C4-584CBED26222 Q27659064-575EDB3D-15EA-422B-8EBA-C99E8544D181 Q27661560-FBDC8B81-8205-42CD-A949-CE21E744167A Q27663665-071DCF85-78C5-4215-A538-D19DFB874840 Q27667504-E7E44E84-9E10-4290-8F6B-B5BCA53868DB Q27679318-5DAF31B1-1366-4F47-88DF-4C1C067CC09B Q28274081-01ABB3BA-EA87-4D91-8150-83BD1149FA4D Q28394424-59340DBE-0912-442F-8E8D-278F6244AC72 Q30699848-93758C59-435B-4117-9E89-B0F0F68357B3 Q33819279-C84521BF-B73E-401F-9722-F7EF1992A1EF Q33890830-D37D0E4D-32CC-4658-AFCA-437C69B222E1 Q34066023-6D711484-94CD-47B2-9F4B-BE38B5E5F1F6 Q34179727-A32AC78C-2244-40A5-B758-A3241E66EB4F Q34208235-62478C87-7ABF-4727-9E26-68E81B0E026C Q34289313-54C684F2-38F8-44F1-84C4-914EFDE3AE27 Q34372400-3FEB8EA5-058C-40F0-9B2D-B6DDB7B01B51 Q34536091-C81C360C-CDF7-4D2D-BECA-947C06803E7B Q34772023-ED1B6936-618F-43B3-91EC-B4CD70E9F6BE Q35126657-AB0B7DD7-BE02-4EB3-AFE0-D56D66451733 Q35199462-74F3C503-7A73-4270-B34D-EFFB21596AA2 Q35608133-477511D3-6099-427F-98A9-2596933F692E Q36020274-77314A54-3FCD-4439-A590-F4B212F79EBF Q36332780-20A91798-95D1-4A8E-BF69-3BB5C838A794 Q36418541-980D9233-8E0D-4CD1-9534-DA679A3766DE Q36594702-54295AAB-0FEC-4357-8801-6B1ECB53EE67 Q36642779-FB5CC788-9CA8-479C-80BC-898AE6C7CD4E Q36708030-FFF4DC72-F941-4928-9391-4426A2D4D3CA Q36911098-1CA3442E-59C9-404C-90DF-666E6898753F Q36920598-CDA3E028-3C2D-4349-884A-AD31DBB22E07 Q36930196-9ABFB30D-6CF5-44C7-AE34-F818D82C6295 Q37038704-9F321E32-48CA-4EEC-A063-85A4CD32FB73 Q37098910-417FB578-A29E-49E3-8174-9A75B94F3894 Q37213786-DEC22BCD-92CF-460D-A879-A5DED015BE88 Q37277350-1CAD4AC4-992C-4440-B65F-B3F3AEE89A1C Q37591564-D4D5B395-8FDB-4ADF-870F-D92BBEC9F2E4

P2860

Cyclooxygenase Allosterism, Fatty Acid-mediated Cross-talk between Monomers of Cyclooxygenase Homodimers.

http://www.wikidata.org/entity/Q37149507

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cyclooxygenase Allosterism, Fa ...... of Cyclooxygenase Homodimers.

@en

Cyclooxygenase Allosterism, Fa ...... of Cyclooxygenase Homodimers.

@nl

type

label

Cyclooxygenase Allosterism, Fa ...... of Cyclooxygenase Homodimers.

@en

Cyclooxygenase Allosterism, Fa ...... of Cyclooxygenase Homodimers.

@nl

prefLabel

Cyclooxygenase Allosterism, Fa ...... of Cyclooxygenase Homodimers.

@en

Cyclooxygenase Allosterism, Fa ...... of Cyclooxygenase Homodimers.

@nl

P1433

Q37149507-17851566-EF5D-489F-8E52-5986B58B6AC3

P1476

Q37149507-64A96799-5009-43D4-BAE9-CF295126FB0E

P2093

Q37149507-1955D3AA-9B9C-488E-B4A6-20886A0D60F3

Q37149507-536E5EC9-5822-4D73-9364-7ED2EDE03DD2

Q37149507-5F0B7AD2-74F3-48BA-8F8B-C9E8BE585E30

Q37149507-62F3F820-BE66-4EF6-B924-6298E01A6F63

Q37149507-74131E75-4DA5-4D1C-B70C-4CEB8EC4D786

Q37149507-D16A2F0E-3B68-400E-8FB1-D93CF865BEAB

Q37149507-E2C2E190-8A65-4F6A-BC54-317EE3554735

P2860

Q37149507-08B22119-708D-49A3-95AB-020AF4767819

Q37149507-0AAD57FA-7569-467A-877D-2206699D03FE

Q37149507-0C40D7D3-DA9C-4472-9AFC-4541F82AD095

Q37149507-264D4F56-F607-430E-A886-ACE0196E0FC9

Q37149507-2657182C-7E72-469E-85FA-86AC70028383

Q37149507-2B9A0572-F66E-4F94-ADB5-7E42A1D46131

Q37149507-2EFA4934-68A0-48CB-BED9-C2A7EA206B79

Q37149507-3724EBF4-98DB-4FC0-AC54-93CC9D57F3CC

Q37149507-4550B91E-9125-4B24-956B-CE73AED453B7

Q37149507-4BF6934A-DD24-404F-AAAB-A0CF3F589A0D

P304

Q37149507-78306E3B-2226-48A7-B169-B05CF70A525C

P31

Q37149507-D97B9894-3734-4235-907C-E2B86F5EB7B9

P356

Q37149507-F55D9BC2-2D94-4EE5-A224-A4B5FF6AFE94

P407

Q37149507-F440D618-A6E9-4DFD-963B-738F3B3A91B4

P433

Q37149507-6F57CB69-B9F1-4DDB-B81F-A4A2E290FF88

P478

Q37149507-DC524BF7-D244-4346-B3B9-0DECCB3CA7B2

P577

Q37149507-B569F3F2-CE7E-48D4-84E0-A7A87623463C

P698

Q37149507-8EF2BCC6-0592-42FD-8F11-5D9A36C81F8C

P921

Q37149507-0DEA3CCA-C239-43F8-86A6-8AA8C6648D5F

P932

Q37149507-DC1546DE-7602-4EBB-9495-BD7FE0644296

P356

P1433

Journal of Biological Chemistry

P1476

Cyclooxygenase Allosterism, Fa ...... of Cyclooxygenase Homodimers.

@en

P2093

Chong Yuan

http://www.w3.org/2001/XMLSchema#string

Dmitry V Kuklev

http://www.w3.org/2001/XMLSchema#string

Inseok Song

http://www.w3.org/2001/XMLSchema#string

Masayuki Wada

http://www.w3.org/2001/XMLSchema#string

Ranjinder S Sidhu

http://www.w3.org/2001/XMLSchema#string

William L Smith

http://www.w3.org/2001/XMLSchema#string

Yuji Kado

http://www.w3.org/2001/XMLSchema#string

P2860

Group VIB Ca2+-independent phospholipase A2gamma promotes cellular membrane hydrolysis and prostaglandin production in a manner distinct from other intracellular phospholipases A2

Structural insights into the stereochemistry of the cyclooxygenase reaction

The productive conformation of arachidonic acid bound to prostaglandin synthase

Structure of eicosapentaenoic and linoleic acids in the cyclooxygenase site of prostaglandin endoperoxide H synthase-1

Structural basis of enantioselective inhibition of cyclooxygenase-1 by S-alpha-substituted indomethacin ethanolamides

The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1

Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents

Synthesis of four isomers of parinaric acid

Function, activity, and membrane targeting of cytosolic phospholipase A(2)zeta in mouse lung fibroblasts

Studies on a mechanism by which cytosolic phospholipase A2 regulates the expression and function of type IIA secretory phospholipase A2

P304

10046-10055

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M808634200

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

284

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19218248

http://www.w3.org/2001/XMLSchema#string

P921

P932

2665059

http://www.w3.org/2001/XMLSchema#string